Vitality Biopharma Stock Price, News & Analysis (OTCMKTS:VBIO)

$1.91 0.00 (0.00 %)
(As of 01/16/2018 02:53 AM ET)
Previous Close$1.91
Today's Range$1.88 - $1.97
52-Week Range$1.30 - $3.12
Volume109,300 shs
Average Volume253,255 shs
Market Capitalization$45.78 million
P/E Ratio-6.16
Dividend YieldN/A
Beta1.4

About Vitality Biopharma (OTCMKTS:VBIO)

Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The Company unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its product pipeline includes cannabosides, VITA-100 and VITA-210. Cannabosides are cannabinoid glycoside prodrugs. VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for treatment of inflammatory bowel disease, epilepsy, schizophrenia, and other disorders. VITA-210 is a cannabinoid glycoside prodrug being developed primarily for treatment of pain and muscle spasticity in multiple sclerosis and in rare white matter disorders. The Company's facilities include laboratories and a manufacturing suite for good manufacturing practices (GMPs) production, which will be used for pharmaceutical-grade production of products to be tested in clinical trials.

Receive VBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:VBIO
CUSIPN/A
Phone530-231-7800

Debt

Debt-to-Equity RatioN/A
Current Ratio1.43%
Quick Ratio1.43%

Price-To-Earnings

Trailing P/E Ratio-6.16109157769104
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$160,000.00
Price / Sales286.14
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book95.50

Profitability

Trailing EPS($0.31)
Net Income$-5,210,000.00
Net Margins-4,355.81%
Return on EquityN/A
Return on Assets-588.47%

Miscellaneous

Employees7
Outstanding Shares23,970,000

Vitality Biopharma (OTCMKTS:VBIO) Frequently Asked Questions

What is Vitality Biopharma's stock symbol?

Vitality Biopharma trades on the OTCMKTS under the ticker symbol "VBIO."

How were Vitality Biopharma's earnings last quarter?

Vitality Biopharma Inc (OTCMKTS:VBIO) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.04) earnings per share for the quarter. View Vitality Biopharma's Earnings History.

Who are some of Vitality Biopharma's key competitors?

Who are Vitality Biopharma's key executives?

Vitality Biopharma's management team includes the folowing people:

  • Avtar S. Dhillon M.D., Chairman of the Board (Age 56)
  • Robert T. Brooke, Chief Executive Officer, Director (Age 36)
  • Anthony E. Maida III, Ph.D., Independent Director (Age 65)

How do I buy Vitality Biopharma stock?

Shares of Vitality Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vitality Biopharma's stock price today?

One share of Vitality Biopharma stock can currently be purchased for approximately $1.91.

How big of a company is Vitality Biopharma?

Vitality Biopharma has a market capitalization of $45.78 million and generates $160,000.00 in revenue each year. The company earns $-5,210,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Vitality Biopharma employs 7 workers across the globe.

How can I contact Vitality Biopharma?

Vitality Biopharma's mailing address is 1901 AVENUE OF THE STARS 2ND FLOOR, LOS ANGELES CA, 90067. The company can be reached via phone at 530-231-7800 or via email at [email protected]


MarketBeat Community Rating for Vitality Biopharma (VBIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  50
MarketBeat's community ratings are surveys of what our community members think about Vitality Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vitality Biopharma (OTCMKTS:VBIO) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Vitality Biopharma (OTCMKTS:VBIO) Earnings History and Estimates Chart

Earnings by Quarter for Vitality Biopharma (OTCMKTS:VBIO)

Vitality Biopharma (OTCMKTS VBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q2 2018($0.04)ViewN/AView Earnings Details
8/10/2017Q1 2018($0.05)ViewN/AView Earnings Details
6/28/2017Q4 2017($0.05)ViewN/AView Earnings Details
2/14/2017Q3 2017($0.06)ViewN/AView Earnings Details
11/17/2016Q2 2017($0.09)ViewN/AView Earnings Details
8/16/2016Q1 2017($0.04)ViewN/AView Earnings Details
6/24/2016Q4 2016($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vitality Biopharma (OTCMKTS:VBIO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vitality Biopharma (OTCMKTS:VBIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vitality Biopharma (OTCMKTS VBIO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Vitality Biopharma (OTCMKTS VBIO) News Headlines

Source:

SEC Filings

Vitality Biopharma (OTCMKTS:VBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vitality Biopharma (OTCMKTS:VBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vitality Biopharma (OTCMKTS VBIO) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.